University of California

Pfizer Corporation

The United States Government As Represented by the Department of Veterans Affairs

Qizhi Tang

Jeffrey A Bluestone

Natasha K Crellin

Lauren K Ely

Matthias Hebrok

Eleonora Trotta

Wenhan Chang

Gopika G Nair

Jason Robles Reyes

Chia Chi Ho

Casey Ward

Peter Stock

Gaetano Faleo

Eleonora De Klerk

Emma Masteller

Thuy Vo

The invention provides LFA3 polypeptide molecules, e.g., variant LFA3 fusion polypeptide molecules. The invention includes uses, and associated methods of using the LFA3 polypeptide molecules.

Lymphocyte function-associated antigen 3 (LFA3) variant polypeptides and methods of use thereof to treat CD2-mediated immune diseases, disorders or conditions

Provided herein, inter alia, are methods and compositions for treating diabetes mellitus comprising co-transplantation of an insulin-producing cell and a cell derived from a parathyroid gland (PTG), a CD34+ cell derived from a parathyroid gland, a CD34+ cell derived from a stem cell, or other progenitor cell-derived CD34+ cell.

Preservation of pancreatic islet grafts in the extrahepatic space

The present disclosure relates generally to the manufacture of regulatory T cells (Tregs) for use in immunotherapy. In particular, the present disclosure relates to robust approaches for the expansion of alloantigen-reactive Tregs ex vivo. Alloantigen-reactive Tregs produced in this way are suitable for the induction and/or maintenance of immunologic tolerance in recipients of allogeneic transplants.

Expansion of alloantigen-reactive regulatory T cells

The invention provides methods for producing an autoantigen-specific regulatory T cell enriched composition, and resultant compositions and methods of use.

Regulatory T cells suppress autoimmunity

Growing community of inventors

San Francisco, CA, United States of America

Qizhi Tang